Joginder Nath
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Joginder Nath has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- John Killefer
Department of Animal Sciences, University of Illinois, Urbana 61801
2 shared publications - Mohamed Salem
Department of Animal and Avian Sciences, University of Maryland, College Park, USA
2 shared publications Alison E. Director
Applied Cellular Radiobiology, Armed Forces Radiobiology Research Institute, Bethesda, Maryland
1 shared publication- Ann F. Hubbs
Health Effects Laboratory Division, National Institute for Occupational Safety and Health, Morgantown, West Virginia 26505, USA
1 shared publication - Brandon F Law
National Institute for Occupational Safety and Health, Center for Disease Control and Prevention, Morgantown, WV 26505, USA
1 shared publication Caird E. Rexroad
National Center for Cool and Cold Water Aquaculture, Kearneysville, WV 25430, USA
1 shared publication
Latest Publications
- Open Access
- 3 August 2009
- Published by Springer Nature in Particle and Fibre Toxicology
- Vol. 6 (1) , 21
Coal dust alters β-naphthoflavone-induced aryl hydrocarbon receptor nuclear translocation in alveolar type II cells
Background: Many polycyclic aromatic hydrocarbons (PAHs) can cause DNA adducts and initiate carcinogenesis. Mixed exposures to coal dust (CD) and PAHs are common in occupational settings. In the CD and PAH-exposed lung, CD increases apoptosis and causes alveolar type II (AT-II) cell hyperplasia but reduces CYP1A1 induction. Inflammation, but not apoptosis, appears etiologically associated with reduced CYP1A1 induction in this mixed exposure model. Many AT-II cells in the CD-exposed lungs have no detectable CYP1A1 induction after PAH exposure. Although AT-II cells are a small subfraction of lung cells, they are believed to be a potential progenitor cell for some lung cancers. Because CYP1A1 is induced via ligand-mediated nuclear translocation of the aryl hydrocarbon receptor (AhR), we investigated the effect of CD on PAH-induced nuclear translocation of AhR in AT-II cells isolated fromin vivo-exposed rats. Rats received CD or vehicle (saline) by intratracheal (IT) instillation. Three days before sacrifice, half of the rats in each group started daily intraperitoneal injections of the PAH, β-naphthoflavone (BNF).Results: Fourteen days after IT CD exposure and 1 day after the last intraperitoneal BNF injection, AhR immunofluorescence indicated that proportional AhR nuclear expression and the percentage of cells with nuclear AhR were significantly increased in rats receiving IT saline and BNF injections compared to vehicle controls. However, in CD-exposed rats, BNF did not significantly alter the nuclear localization or cytosolic expression of AhR compared to rats receiving CD and oil.Conclusion: Our findings suggest that during particle and PAH mixed exposures, CD alters the BNF-induced nuclear translocation of AhR in AT-II cells. This provides an explanation for the modification of CYP1A1 induction in these cells. Thus, this study suggests that mechanisms for reduced PAH-induced CYP1A1 activity in the CD exposed lung include not only the effects of inflammation on the lung as a whole, but also reduced PAH-associated nuclear translocation of AhR in an expanded population of AT-II cells.
- 3 August 2009
- Published by Springer Nature in Particle and Fibre Toxicology
- Vol. 6 (1) , 21
Open AccessCoal dust alters β-naphthoflavone-induced aryl hydrocarbon receptor nuclear translocation in alveolar type II cells
Background: Many polycyclic aromatic hydrocarbons (PAHs) can cause DNA adducts and initiate carcinogenesis. Mixed exposures to coal dust (CD) and PAHs are common in occupational settings. In the CD and PAH-exposed lung, CD increases apoptosis and causes alveolar type II (AT-II) cell hyperplasia but reduces CYP1A1 induction. Inflammation, but not apoptosis, appears etiologically associated with reduced CYP1A1 induction in this mixed exposure model. Many AT-II cells in the CD-exposed lungs have no detectable CYP1A1 induction after PAH exposure. Although AT-II cells are a small subfraction of lung cells, they are believed to be a potential progenitor cell for some lung cancers. Because CYP1A1 is induced via ligand-mediated nuclear translocation of the aryl hydrocarbon receptor (AhR), we investigated the effect of CD on PAH-induced nuclear translocation of AhR in AT-II cells isolated fromin vivo-exposed rats. Rats received CD or vehicle (saline) by intratracheal (IT) instillation. Three days before sacrifice, half of the rats in each group started daily intraperitoneal injections of the PAH, β-naphthoflavone (BNF).Results: Fourteen days after IT CD exposure and 1 day after the last intraperitoneal BNF injection, AhR immunofluorescence indicated that proportional AhR nuclear expression and the percentage of cells with nuclear AhR were significantly increased in rats receiving IT saline and BNF injections compared to vehicle controls. However, in CD-exposed rats, BNF did not significantly alter the nuclear localization or cytosolic expression of AhR compared to rats receiving CD and oil.Conclusion: Our findings suggest that during particle and PAH mixed exposures, CD alters the BNF-induced nuclear translocation of AhR in AT-II cells. This provides an explanation for the modification of CYP1A1 induction in these cells. Thus, this study suggests that mechanisms for reduced PAH-induced CYP1A1 activity in the CD exposed lung include not only the effects of inflammation on the lung as a whole, but also reduced PAH-associated nuclear translocation of AhR in an expanded population of AT-II cells.
- 28 June 2005
- Published by Elsevier in Comparative Biochemistry and Physiology Part B: Biochemistry and Molecular Biology
- Vol. 141 (4) , 488-497
Characterization of calpastatin gene in fish: Its potential role in muscle growth and fillet quality
- 28 June 2005
- Published by Elsevier in Comparative Biochemistry and Physiology Part B: Biochemistry and Molecular Biology
- Vol. 141 (4) , 488-497
Characterization of calpastatin gene in fish: Its potential role in muscle growth and fillet quality
- 1 October 2004
- Published by Wiley in Journal of Muscle Foods
- Vol. 15 (4) , 245-255
ISOLATION AND CHARACTERIZATION OF CALPAINS FROM RAINBOW TROUT MUSCLE AND THEIR ROLE IN TEXTURE DEVELOPMENT
A single anion‐exchange column was used to resolve calpain I and II and their endogenous inhibitor, calpastatin, from the white muscle of rainbow trout (Oncorhynchus mykiss). Calcium requirement assays showed that calpain I and II required approximately 0.2 mM and 2.5 mM, respectively, for half maximal activities. Isolation of calpain I and calpastatin were confirmed by Western blot. Incubation of trout muscle for 12 h postmortem, in a buffer containing CaCl2, decreased (P < 0.0001) shear force compared to samples incubated in a buffer containing EDTA. This effect indicates that softening of fish muscle can be accelerated by activation of calpains with exogenous calcium.
- 1 October 2004
- Published by Wiley in Journal of Muscle Foods
- Vol. 15 (4) , 245-255
ISOLATION AND CHARACTERIZATION OF CALPAINS FROM RAINBOW TROUT MUSCLE AND THEIR ROLE IN TEXTURE DEVELOPMENT
A single anion‐exchange column was used to resolve calpain I and II and their endogenous inhibitor, calpastatin, from the white muscle of rainbow trout (Oncorhynchus mykiss). Calcium requirement assays showed that calpain I and II required approximately 0.2 mM and 2.5 mM, respectively, for half maximal activities. Isolation of calpain I and calpastatin were confirmed by Western blot. Incubation of trout muscle for 12 h postmortem, in a buffer containing CaCl2, decreased (P < 0.0001) shear force compared to samples incubated in a buffer containing EDTA. This effect indicates that softening of fish muscle can be accelerated by activation of calpains with exogenous calcium.
- 1 January 2000
- Published by Taylor & Francis in Biotechnic & Histochemistry
- Vol. 75 (2) , 54-78
A Review of Fluorescence in Situ Hybridization (FISH): Current Status and Future Prospects
Fluorescence in situ hybridization (FISH) is a powerful technique for detecting DNA or RNA sequences in cells, tissues and tumors. This molecular cytogenetic technique enables the localization of specific DNA sequences within interphase chromatin and metaphase chromosomes and the identification of both structural and numerical chromosome changes. FISH is quickly becoming one of the most extensively used cytochemical staining techniques owing to its sensitivity and versatility, and with the improvement of current technology and cost effectiveness, its use will surely continue to expand. Here we review the wide variety of current applications and future prospects of FISH technology.
- 1 January 2000
- Published by Taylor & Francis in Biotechnic & Histochemistry
- Vol. 75 (2) , 54-78
A Review of Fluorescence in Situ Hybridization (FISH): Current Status and Future Prospects
Fluorescence in situ hybridization (FISH) is a powerful technique for detecting DNA or RNA sequences in cells, tissues and tumors. This molecular cytogenetic technique enables the localization of specific DNA sequences within interphase chromatin and metaphase chromosomes and the identification of both structural and numerical chromosome changes. FISH is quickly becoming one of the most extensively used cytochemical staining techniques owing to its sensitivity and versatility, and with the improvement of current technology and cost effectiveness, its use will surely continue to expand. Here we review the wide variety of current applications and future prospects of FISH technology.
- 21 December 1998
- Published by Wiley in Environmental and Molecular Mutagenesis
- Vol. 32 (2) , 139-147
Chronic ingestion of clastogens by mice and the frequency of chromosome aberrations
- 21 December 1998
- Published by Wiley in Environmental and Molecular Mutagenesis
- Vol. 32 (2) , 139-147
Chronic ingestion of clastogens by mice and the frequency of chromosome aberrations
- 1 April 1998
- Published by S. Karger AG in Acta Haematologica
- Vol. 99 (3) , 138-147
Safety Screening of Drugs in Cancer Therapy
Development of new drugs requires a thorough investigation of efficacy and safety of pharmaceuticals. The potential risks and benefits of drugs used in chemotherapy are carefully considered such that the benefits of using a new drug outweigh the risks in terms of the side effects caused by the drug. Damage to normal cells, tissues, organs and/or the whole organism is a big concern. Several tests are now routinely performed and are required for drug approval by various regulatory agencies around the globe. The primary goals of such preclinical safety evaluation of drugs are: (1) to identify an initial safe starting dose and subsequent dose escalation scheme to humans; (2) to identify potential target organs of toxicity and reversibility of toxicity; (3) to identify potential damage to the genetic material (genotoxicity); and (4) to identify parameters of clinical monitoring. In this paper, various models for genotoxicity assays are presented. These include: Ames assay, in vitro chromosome aberration assay and an in vivo micronucleus assay. New technologies, such as DNA adduct formation, DNA strand breakage, apoptotic changes, p53 gene expression and transgenic animal models, are also considered.
- 1 April 1998
- Published by S. Karger AG in Acta Haematologica
- Vol. 99 (3) , 138-147
Safety Screening of Drugs in Cancer Therapy
Development of new drugs requires a thorough investigation of efficacy and safety of pharmaceuticals. The potential risks and benefits of drugs used in chemotherapy are carefully considered such that the benefits of using a new drug outweigh the risks in terms of the side effects caused by the drug. Damage to normal cells, tissues, organs and/or the whole organism is a big concern. Several tests are now routinely performed and are required for drug approval by various regulatory agencies around the globe. The primary goals of such preclinical safety evaluation of drugs are: (1) to identify an initial safe starting dose and subsequent dose escalation scheme to humans; (2) to identify potential target organs of toxicity and reversibility of toxicity; (3) to identify potential damage to the genetic material (genotoxicity); and (4) to identify parameters of clinical monitoring. In this paper, various models for genotoxicity assays are presented. These include: Ames assay, in vitro chromosome aberration assay and an in vivo micronucleus assay. New technologies, such as DNA adduct formation, DNA strand breakage, apoptotic changes, p53 gene expression and transgenic animal models, are also considered.